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Abstract
Introduction: Biomarkers can be useful for identifying or ruling out sepsis, identifying patients who may benefit
from specific therapies or assessing the response to therapy.
Methods: We used an electronic search of the PubMed database using the key words “sepsis” and “biomarker” to
identify clinical and experimental studies which evaluated a biomarker in sepsis.
Results: The search retrieved 3370 references covering 178 different biomarkers.
Conclusions: Many biomarkers have been evaluated for use in sepsis. Most of the biomarkers had been tested
clinically, primarily as prognostic markers in sepsis; relatively few have been used for diagnosis. None has sufficient
specificity or sensitivity to be routinely employed in clinical practice. PCT and CRP have been most widely used,
but even these have limited ability to distinguish sepsis from other inflammatory conditions or to predict outcome.
Introduction
Sepsis is a leading cause of death in critically ill patients
despite the use of modern antibiotics and resuscitation
therapies [1]. The septic response is an extremely com-
plex chain of events involving inflammatory and anti-
inflammatory processes, humoral and cellular reactions
and circulatory abnormalities [2,3]. The diagnosis of
sepsis and evaluation of its severity is complicated by
the highly variable and non-specific nature of the signs
and symptoms of sepsis [4]. However, the early diagno-
sis and stratification of the severity of sepsis is very
important, increasing the possibility of starting timely
and specific treatment [5,6].
Biomarkers can have an important place in this pro-
cess because they can indicate the presence or absence
or severity of sepsis [7,8], and can differentiate bacterial
from viral and fungal infection, and systemic sepsis from
local infection. Other potential uses of biomarkers
include roles in prognostication, guiding antibiotic ther-
apy, evaluating the response to therapy and recovery
from sepsis, differentiating Gram-positive from Gram-
negative microorganisms as the cause of sepsis, predict-
ing sepsis complications and the development of organ
dysfunction (heart, kidneys, liver or multiple organ dys-
function). However, the exact role of biomarkers in the
management of septic patients remains undefined [9].
C-reactive protein (CRP) has been used for many years
[10,11] but its specificity has been challenged [12]. Pro-
calcitonin (PCT) has been proposed as a more specific
[13] and better prognostic [14] marker than CRP,
although its value has also been challenged [15]. It
remains difficult to differentiate sepsis from other non-
infectious causes of systemic inflammatory response
syndrome [16], and there is a continuous search for bet-
ter biomarkers of sepsis.
With this background in mind, we reviewed the litera-
ture on sepsis biomarkers that have been used in clinical
or experimental studies to help better evaluate their
utility.
Materials and methods
The entire Medline database was searched in February
2009 using the key words ‘sepsis’ and ‘biomarker’.A l l
studies, both clinical and experimental, which evaluated
a biomarker were included. For each identified biomar-
ker, the Medline database was searched again using the
biomarker name and the key word ‘biomarker’.
Results
A total of 3370 studies that assessed a biomarker in sep-
sis were retrieved; 178 different biomarkers were evalu-
ated in the 3370 studies. The retrieved biomarkers and
the major findings from key studies using these biomar-
k e r sa r el i s t e di nT a b l e s1 ,2 ,3 ,4 ,5 ,6 ,7 ,8a n d9 .O f
the 178 biomarkers, 18 had been evaluated in
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clinical studies, and 101 in clinical studies only. Thirty-
four biomarkers were identified that have been assessed
for use specifically in the diagnosis of sepsis (Table 10);
of these just five reported sensitivity and specificity
values greater than 90%.
Discussion
A multitude of biomarkers has been proposed in the
field of sepsis, many more than in other disease pro-
cesses; for example, a study of patients with myocardial
infarction revealed 14 biomarkers suitable for diagnosis
and determination of prognosis [17] and in patients
with Alzheimer’s disease, just 8 biomarkers were identi-
fied [18]. This large difference in the numbers of bio-
markers for sepsis is likely to be related to the very
complex pathophysiology of sepsis, which involves many
mediators of inflammation [19], but also other patho-
physiological mechanisms. Coagulation, complement,
contact system activation, inflammation, and apoptosis
are all involved in the sepsis process, and separate mar-
kers for each (part of each) system have been proposed
(Tables 1 to 9). Additionally, the systemic nature of sep-
sis and the large numbers of cell types, tissues and
organs involved expand the number of potential biomar-
ker candidates, compared with disease processes that
involve individual organs or are more localized.
It is interesting to note that most of the biomarkers
we identified have been tested clinically and not experi-
mentally. This is likely to be in part related to difficul-
ties creating an experimental model that accurately
reflects all aspects of human sepsis, problems with spe-
cies differences, and problems in determining end-points
in animal studies. Additionally, as the sepsis response
varies with time, the exact time period during which
any specific biomarker may be useful varies, and this is
difficult to assess reliably in experimental models. More-
over, as there is no ‘gold standard’ for the diagnosis of
Table 1 Cytokine/chemokine biomarkers identified in the literature search (with some selected references)
Sepsis marker Evaluated in
experimental
studies
Evaluated in
clinical studies
Evaluated as a
prognostic factor
Comment
GRO-alpha [49,50] √ C (m) √ Higher in septic shock than in sepsis
High mobility group-box 1
protein (HMGB-1) [51,52]
√ C √ No difference between survivors and non-survivors at
28 days
IL-1 receptor antagonist [53-55] √ A √ Correlation with SOFA score
IL-1b [56,57] √ A Increased in septic compared with non-septic
individuals
IL-2 [58] B √ Increased in parallel with disease severity
IL-4 [59] C (s) √ Increased levels associated with development of
sepsis
IL-6 [48,60] √ B √* Distinguished between survivors and non-survivors at
28 days
IL-8 [61,62] B √*** Prediction of MOF, DIC
IL-10 [63-65] √ B √** Higher in septic shock than sepsis, distinguished
between survivors and non-survivors at 28 days
IL-12 [66,67] √ C √ Predictive of lethal outcome from postoperative
sepsis
IL-13 [68,69] √ B √ Higher in septic shock than sepsis
IL-18 [37,70] √ B(s) √ Distinguished between survivors and non-survivors at
28 days
Macrophage inflammatory
protein (MIP)-1 and- 2 [71,72]
√ A √ Increased in sepsis compared with healthy controls
Macrophage migration
inhibitory factor (MIF) [42,73]
√ A √** Distinguished between survivors and non-survivors at
28 days
Monocyte chemotactic protein
(MCP)-1 and 2 [42,74]
√ B √* Distinguished between survivors and non-survivors at
28 days
Osteopontin [75] B Increased in sepsis compared with healthy controls
RANTES [76,77] √ B Increased in sepsis compared with healthy controls
TNF [78,79] √ C √ Distinguished between survivors and non-survivors at
28 days in patients with septic shock
*sensitivity and specificity of less than 90%; **sensitivity of more than 90% but specificity of less than 90%; ***sensitivity and specificity more than 90%; A,
Clinical study with less than 20 patients; B, Clinical study with 20 to 50 patients; C, Clinical study with more than 50 patients; (s), surgical patients only; (m),
medical patients only.
DIC: disseminated intravascular coagulopathy; MOF: multiple organ failure; SOFA: sequential organ failure assessment.
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pared with current methods used to diagnose and moni-
tor sepsis in everyday clinical practice, i.e., by the
combination of clinical signs and available laboratory
variables [20]; experimental models cannot be used for
this purpose.
Our study revealed that there are many more potential
biomarkers for sepsis than are currently used in clinical
studies. Some of these markers may require considerable
time, effort and costs to measure. Some are already rou-
tinely used for other purposes and easily obtained, such
as coagulation tests or cholesterol concentrations. In
many cases, the reliability and validity of the proposed
biomarker have not been tested properly [8]. Of the
many proposed markers for sepsis, acute phase proteins
have perhaps been most widely assessed. PCT has been
used particularly extensively in recent years. The specifi-
city and sensitivity of PCT for the diagnosis of sepsis is
relatively low (typically below 90%), regardless of the
cut-off value [21,22]. Raised PCT levels have also been
reported in other conditions associated with inflamma-
tory response, such as trauma [23], major surgery [24]
and cardiac surgery [25]. Although CRP is often
reported as inferior compared with PCT in terms of
sepsis diagnosis, it is frequently used in clinical practice
because of its greater availability. Elevated concentra-
tions of serum CRP are correlated with an increased
risk of organ failure and death [26], and the study of its
time course may be helpful to evaluate the response to
therapy in septic patients [11].
Another group of compounds that has been widely
assessed as potential biomarkers are the cytokines.
These are important mediators in the pathophysiology
of sepsis, and most are produced fairly rapidly after sep-
sis onset. In a clinical study, levels of TNF and IL-10
were increased within the first 24 hours after admission
of the patient [27]. However, blood cytokine concentra-
tions are rather erratic and their time course is not
clearly in concert with the course of sepsis [27,28], mak-
ing interpretation difficult.
The diagnosis of sepsis is a challenge. Clinical and
standard laboratory tests are not very helpful because
most critically ill patients develop some degree of
inflammatory response, whether or not they have sepsis.
Even microbiological assessment is unreliable because
many culture samples do not yield microorganisms in
these patients. However, biomarkers have also not been
shown to be a great asset in the diagnosis of sepsis.
Indeed, relatively few biomarkers have been evaluated as
diagnostic markers (Table 10). Our search retrieved only
10 biomarkers that have been assessed for their ability
to distinguish septic patients from non-septic patients
with systemic immune response syndrome. However,
none of these biomarkers has been tested for both sensi-
tivity and specificity, and there is therefore no biomarker
clearly identified as being able to differentiate sepsis
Table 2 Cell marker biomarkers identified in the literature search (with some selected references)
Sepsis Marker Evaluated in
experimental
studies
Evaluated in
clinical studies
Evaluated as a
prognostic factor
Comment
CD10 [80,81] √ A Decreased in septic shock compared with healthy controls
CD11b [82,83] √ B(s) √ Correlation with SOFA score
CD11c [84] A Decreased in septic shock compared with healthy controls
CD14 (cellular and
soluble) [85]
C √ Distinguished between survivors and non-survivors at
28 days
CD18 [86] √
CD25 (cellular and
soluble) [87]
A Distinguished between survivors and non-survivors at
28 days
CD28 (soluble) [88] B √ Distinguished between survivors and non-survivors at
28 days
CD40 (cellular and
soluble) [89]
B √ Distinguished between survivors and non-survivors at
28 days
CD48 [90] B Increased in sepsis compared with healthy controls
CD64 [91] B √ Correlation with APACHE II and SOFA scores
CD69 [92] A Increased in sepsis compared with healthy controls
CD80 [88] B √ Predicted development of septic shock
CD163 (soluble) [93] C √ Distinguished between survivors and non-survivors at
28 days
mHLA-DR (soluble) [94] C √* Distinguished between survivors and non-survivors at
28 days in patients with septic shock
*sensitivity and specificity of less than 90%; A, Clinical study with less than 20 patients; B, Clinical study with 20 to 50 patients; C, Clinical study with more than
50 patients; (s), surgical patients only.
APACHE: acute physiology and chronic health evaluation; SOFA: sequential organ failure assessment.
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Sepsis marker Evaluated in
experimental
studies
Evaluated in
clinical studies
Evaluated as a
prognostic factor
Comment
CC chemokine receptor (CCR) 2 [95] √
CCR 3 [96] C √ Distinguished between survivors and non-
survivors at 28 days
C5L2 [97] √ B √ Predicted development of MOF
CRTh2 [98] C √ Distinguished between survivors and non-
survivors at 28 days
Fas receptor (soluble) [99] B(m) √ Predicted development of MOF
Fc-gamma RIII [100] A √ Increased in sepsis compared with healthy
controls, correlated with APACHE II score
FLT-1 (soluble) [101,102] √ C √ Correlated with APACHE II score
GP130 [103] A Increased in sepsis compared with healthy
controls
IL-2 receptor (soluble) [104] C √ Predicted development of septic shock
Group II phospholipase A2 (PLA2-II)
(soluble) [105,106]
√ B Distinguished between survivors and non-
survivors at 28 days
RAGE (soluble) [107] B √* Distinguished between survivors and non-
survivors at 28 days
ST2 (soluble, IL-1 receptor) [108] A(s) √ Increased in sepsis compared with healthy
controls
Toll-like receptor (TLR) 2 and 4 [109] √ B √ Increased in septic compared with non-septic
critically ill patients
Transient receptor potential vanilloid
(TRPV)1 [110]
√
TREM-1 (soluble) [111,112] √ C √ Distinguished between survivors and non-
survivors at 28 days
TNF-receptor (soluble) [113] B Predicted development of MOF
Urokinase type plasminogen activator
receptor (uPAR) (soluble) [114]
C(m) √ Distinguished between survivors and non-
survivors at 28 days
*sensitivity and specificity of less than 90%; A, Clinical study with less than 20 patients; B, Clinical study with 20 to 50 patients; C, Clinical study with more than
50 patients; (s), surgical patients only; (m), medical patients only.
APACHE: acute physiology and chronic health evaluation; MOF: multiple organ failure; TREM: triggering receptor expressed on myeloid cells; RAGE: receptor for
advanced glycation end-products.
Table 4 Coagulation biomarkers identified in the literature search (with some selected references)
Sepsis marker Evaluated in
experimental
studies
Evaluated in
clinical studies
Evaluated as a
prognostic factor
Comment
Antithrombin [115] √ B √** Distinguished between survivors and non-survivors at
28 days
Activated partial
thromboplastin time (aPTT)
[35]
C √ Correlated with MOF score in patients with sepsis and
DIC, high negative predictive value
D-dimers, TAT, F1.2, PT
[116]
C √ Distinguished between survivors and non-survivors at
28 days, correlated with APACHE II score
Fibrin [36] C Increased in patients with Gram-negative bacteremia
PF-4 [117] A √ Predicted response to therapy
Plasminogen activator
inhibitor (PAI)-1 [118,119]
B √ Distinguished between survivors and non-survivors at
28 days, predicted development of MOF
Protein C and S [120,121] √ C √* Distinguished between survivors and non-survivors at
28 days
Thrombomodulin [122,123] √ C √ Predicted development of MOF, DIC, and response to
therapy
*sensitivity and specificity of less than 90%; **sensitivity of more than 90% but specificity of less than 90%; A, Clinical study with less than 20 patients; B, Clinical
study with 20 to 50 patients; C, Clinical study with more than 50 patients.
APCHE: acute physiology and chronic health evaluation; DIC: disseminated intravascular coagulopathy; MOF: multiple organ failure; PT: prothrombin time; PF:
platelet factor; TAT: thrombin-antithrombin complex.
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references)
Sepsis marker Evaluated in
experimental
studies
Evaluated in
clinical
studies
Evaluated as a
prognostic
factor
Comment
ADAMTS-13 [124,125] √ B √ Decreased in septic patients with DIC compared
with no DIC
Angiopoietin (1 and 2) [126] B √ Distinguished between survivors and non-survivors
at 28 days
Endocan [127,128] √ B √ Predicted development of septic shock
Endothelial leukocyte adhesion
molecule (ELAM)-1 (cellular and
soluble) [129,130]
√ B(s) √* Distinguished between survivors and non-survivors
at 28 days
Endothelial progenitor cells (cEPC) [131] B √ Distinguished between survivors and non-survivors
at 28 days
Intracellular adhesion molecule (ICAM)-
1 (soluble) [38]
√ B(m) √
Laminin [132] A Increased in sepsis compared with non-infected
controls
Neopterin [133,134] √ C √* Distinguished between survivors and non-survivors
at 28 days
Platelet-derived growth factor (PDGF)-
BB [135]
B √ Distinguished between survivors and non-survivors
at 28 days in patients with severe sepsis
E-Selectin (cellular and soluble)
[123,136]
√ C √ Predicted development of MOF, correlated with
SAPS score
L-Selectin (soluble) [137] C √* Distinguished between survivors and non-survivors
at 28 days
P-Selectin [138] √
Vascular cell adhesion molecule
(VCAM)-1 [139,140]
√ C Predicted development of MOF
Vascular endothelial growth factor
(VEGF) [141,142]
√ A √ Distinguished between survivors and non-survivors
at 28 days, predicted development of MOF
von Willebrand factor and antigen
[143,144]
B(m) √ Distinguished between survivors and non-survivors
at 28 days, predicted development of acute lung
injury
*sensitivity and specificity of less than 90%; A, Clinical study with less than 20 patients; B, Clinical study with 20 to 50 patients; C, Clinical study with more than
50 patients; (s), surgical patients only; (m), medical patients only.
DIC: disseminated intravascular coagulopathy; MOF: meultiple organ failure; SAPS: simplified acute physiology score.
Table 6 Biomarkers related to vaosdilation identified in the literature search (with some selected references)
Sepsis marker Evaluated in
experimental
studies
Evaluated in
clinical
studies
Evaluated as a
prognostic
factor
Comment
Adrenomedullin and pro-
adrenomedullin [145,146]
B √* Predicted development of septic shock
Anandamide [147] √ A Increased in sepsis compared with healthy controls
Angiotensin converting enzyme
(ACE) (activity and serum)
[148,149]
√ B Increased in sepsis compared with healthy controls
2-arachidonoylglycerol [150] A Increased in sepsis compared with healthy controls
Copeptin [151] C(m) √* Distinguished between survivors and non-survivors at 28
days, correlated with APACHE II score
C-type natriuretic peptide (CNP)
[152]
A Increased in patients with septic shock compared with
healthy controls
Cycling nucleotides [153,154] √ A(m) √ Distinguished between survivors and non-survivors at 28
days
Elastin [155] B Decreased in sepsis compared with healthy controls
cGRP [156,157] √ C(s) √ Distinguished between survivors and non-survivors at 28
days, correlated with APACHE II score
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(Continued)
47 kD HK [158] B(m) Correlated with severity of sepsis
Neuropeptide Y [159,160] √ A Increased in sepsis compared with healthy controls
Nitric oxide (NO), nitrate, nitrite
[161,162]
√ B √ Predicted development of septic shock
Substance P [156,163] √ C(s) √ Distinguished between survivors and non-survivors at 28
days (predictive only in the late phase of sepsis, 2 days
before death)
Tetrahydrobiopterin [164,165] A Increased in sepsis compared with non-septic critically ill
patients
Vasoactive intestinal peptide
(VIP) [166,167]
√ A Increased in tissue samples from patients with peritonitis
compared with no peritonitis
*sensitivity and specificity of less than 90%; A, Clinical study with less than 20 patients; B, Clinical study with 20 to 50 patients; C, Clinical study with more than
50 patients; (s), surgical patients only; (m), medical patients only.
APACHE: acute physiology and chornic health evaluation; cGRP: calcitonin gene-related peptide; HK: high-molecular weight kininogen.
Table 7 Biomarkers of organ dysfunction identified in the literature search (with some selected references)
Sepsis marker Evaluated in
experimental
studies
Evaluated in
clinical studies
Evaluated as a
prognostic factor
Comment
Atrial natriuretic peptide (ANP)
[168,169]
C √* Distinguished between survivors and non-survivors
at 28 days
Brain natriuretic peptide (BNP)
[170-172]
B √** Distinguished between survivors and non-survivors
at 28 days, correlated to APACHE II score
Carbomyl phosphate synthase
(CPS)-1 [173]
√
Endothelin-1 and pro-endothelin-
1 [174-177]
√ B √ Distinguished between survivors and non-survivors
at 28 days, correlated with SOFA score
Filterable cardiodepressant
substance (FCS) [178]
√
Gc-globulin [179] C(s) Predicted development of MOF
Glial fibrillary acidic protein (GFAP)
[180]
B √ Increased in septic shock compared with healthy
controls
alpha glutathione S-transferase
(GST) [181]
√
Hepatocyte growth factor (HGF)
(cellular and soluble) [182,183]
√ C(m) Predicted response to therapy
MEGX test [184,185] √ A √ Correlated with SAPS II score
Myocardial angiotensin II [186] √
NSE [187] B √ Correlated with SOFA scores
Pancreatitis-associated protein-I
[188]
√
Pre B cell colony-enhancing factor
(PBEF) [189]
A Increased in sepsis compared with healthy controls
Protein S-100b [187,190] √ B √ Distinguished between survivors and non-survivors
at 28 days, correlated with SOFA score
Surfactant protein (A, B, C, D)
[191,192]
√ A Increased in sepsis compared with healthy controls
Troponin [193] B √ Distinguished between survivors and non-survivors
at 28 days, correlated with APACHE II score
*sensitivity and specificity of less than 90%; **sensitivity of more than 90% but specificity of less than 90%; A, Clinical study with less than 20 patients; B, Clinical
study with 20 to 50 patients; C, Clinical study with more than 50 patients; (s), surgical patients only; (m), medical patients only.
APACHE: acute physiology and chronic health evaluation; MEGX: monoethylglycinexylidide; MOF: multiple organ failure; NSE: neuron-specific enolase; SAPS:
simplified acute physiology score; SOFA: sequential organ failure assessment.
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causes.
Early diagnosis of sepsis is also an important issue as
early institution of appropriate therapy, including anti-
biotics, is associated with improved outcomes. We iden-
tified 16 factors that have been evaluated specifically for
the early diagnosis of sepsis; five of these had reported
sensitivity and specificity of more than 90%. IL-12 was
measured in newborns at the time when sepsis was first
suspected clinically and was higher in patients with sep-
sis than in those without [29]. Interferon-induced pro-
tein 10 (IP-10) was higher in neonates with sepsis and
necrotizing enterocolitis than in neonates who had only
necrotizing enterocolitis [ 3 0 ] .T h e s et w ob i o m a r k e r s
have not been evaluated for this purpose in adults.
Group II phospholipase 2 (PLA2-II) was reported to
have high sensitivity and specificity for the diagnosis of
bacteremia in critically ill adult patients within 24 hours
after admission [31]. CD64 had high sensitivity and spe-
cificity for the early diagnosis of sepsis in adults, but
could not reliably distinguish viral from bacterial infec-
tions, or local infection from systemic sepsis [32]. Neu-
trophil CD11b could distinguish septic pediatric patients
from those with possible infection with good sensitivity
and specificity [33]. The sensitivity and specificity of the
other 11 biomarkers used to diagnose early sepsis were
not reported or were less than 90%.
Biomarkers can be more useful to rule out sepsis than
to rule it in. We identified three biomarkers with high
negative predictive value to rule out sepsis: PCT (99% at
a cut-off value of 0.2 ng/ml) [34]; activated partial
thromboplastin time (aPTT) waveform (96%) [35]; and
fibrin degradation products (100% for Gram-negative
sepsis by ELISA assay) [36]. It is important to emphasize
that culture-positive sepsis was generally used as the
gold standard in all these studies, although cultures may
remain negative in many patients with sepsis.
The majority of the biomarkers that we identified in
our search were assessed for their ability to differenti-
ate patients likely to survive from those likely to die.
Indeed, any biomarker is expected to have some prog-
nostic value and sepsis biomarkers are no exception;
however, this is not an absolute rule because some
sepsis biomarkers failed to have prognostic value
[37-39]. Moreover, sensitivity and specificity were
tested in only some of the proposed prognostic mar-
kers, and none had sufficient (more than 90%) sensitiv-
ity and specificity to predict which patients were at
greater risk of dying due to sepsis. Other biomarkers
were assessed for their ability to predict the develop-
ment of multiple organ failure and to evaluate
response to therapy. It is known that the extent of
infection and the severity of organ failure has a signifi-
cant impact on the prognosis of patients with sepsis.
Additionally, the response to therapy varies among
patients. Recently, the PIRO model has been proposed
as a way of stratifying septic patients according to
their Predisposing condition, the severity of Infection,
the Response to therapy and the degree of Organ dys-
function [20]. In the future, sepsis biomarkers may
contribute to this model of classification rather than
just being used as prognostic markers.
Table 8 Acute phase protein biomarkers identified in the literature search (with some selected references)
Sepsis Marker Evaluated in
experimental
studies
Evaluated in
clinical studies
Evaluated as a
prognostic factor
Comment
Serum amyloid A (SAA)
[194,195]
√ B(s) √ Correlated with CRP in patients with septic shock
Ceruloplasmin [196,197] A √ Predicted liver dysfunction in patients with sepsis
C-reactive protein (CRP)
[11,198,199]
C √* Predicted response to therapy
Ferritin [200] B(m) √ Distinguished between survivors and non-survivors at
28 days, correlated with SOFA score
Alpha1-acid glycoprotein
[201,202]
√ B √ Distinguished between survivors and non-survivors at
28 days, correlated with SOFA score
Hepcidin [203] B Incraesed in sepsis compared with healthy controls
and patients with chronic renal failure
Lipopolysaccharide binding
protein (LBP) [39,204]
√ C(s) √ Higher in sepsis compared with no sepsis, no
prognostic value
Procalcitonin [21,134,205] √ C √* Increased in infected compared with non-infected
patients
Pentraxin 3 [206,207] C √ Distinguished between survivors and non-survivors at
28 days, correlated with APACHE II score
*sensitivity and specificity of less than 90%; A, Clinical study with less than 20 patients; B, Clinical study with 20 to 50 patients; C, Clinical study with more than
50 patients; (s), surgical patients only; (m), medical patients only.
APACHE: acute physiology and chronic health evaluation; SOFA: sequential organ failure assessment.
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Sepsis marker Evaluated in
experimental
studies
Evaluated in
clinical
studies
Evaluated as a
prognostic
factor
Comment
Alpha2 macroglobulin
[196,208]
√
Albumin [209] √
Anti-endotoxin core
antibodies (EndoCab) [210]
A √ Distinguished between survivors and non-survivors at 28 days
Apolipoprotein CI [211-213] C √ Distinguished between survivors and non-survivors at 28 days
Bcl-2 [214] A √ Distinguished between survivors and non-survivors at 28 days
Beta-thromboglobulin [215] B √ Predicted response to therapy
Caspase-1 [216] A Increased in septic shock compared with healthy controls
Ceramide [217] B √** Predicted development of MOF
Cholesterol [218] C √ Distinguished between survivors and non-survivors at 28 days
in patients with severe sepsis
Complement (C3, C4, C5a
levels) [219,220]
B(m) √ Distinguished between survivors and non-survivors at 28 days
Terminal complement
complex [221]
√
Dendritic cell [222,223] √ B √ Distinguished between survivors and non-survivors at 28 days,
correlated with SOFA score
Dipeptidylpeptidase [224] B Decreased in sepsis compared with healthy controls
Diiodotyrosine (DIT) [225] C √ Increased in sepsis compared with non-septic critically ill
Eicosanoid [226,227] √ A(s) √ Correlated with SAPS score, predicted response to therapy
Elastase [228,229] √ C(s) √ Predicted response to therapy in patients with joint infections
Elastase-a1-antitrypsin
complex [230,231]
C √ Predicted response to therapy
Erythropoietin [232] A √ Distinguished between survivors and non-survivors at 28 days
in patients with septic shock, correlated with lactate levels
F2 isoprostanes [233] B(m) √ Increased in infected diabetic patients compared with non-
infected diabetics
Fatty acid amide hydrolase
[234]
A √ Decreased in sepsis compared with healthy controls
Free DNA [235] B √* Distinguished between survivors and non-survivors at 28 days
G-CSF and GM-CSF
[236,237]
B √** Distinguished between survivors and non-survivors at 28 days
Gelsolin [238] B(s) √ Distinguished between survivors and non-survivors at 28 days
Ghrelin [239,240] √
Growth arrest specific
protein (Gas) 6 [241]
B √ Correlated with APACHE II score in patients with severe sepsis
Heat shock protein (HSP)70,
72, 73, 90 and 32 [242-245]
√ C(s) Increased in sepsis compared with healthy controls
HDL cholesterol C √** Distinguished between survivors and non-survivors at 28 days,
predicted polonged ICU length of stay
HLA-G5 protein (soluble)
[246]
C(m) √* Distinguished between survivors and non-survivors at 28 days
in patients with septic shock
H2S [247] √
Hyaluronan [248,249] √ B Distinguished between survivors and non-survivors at 28 days
in patients with septic shock
Hydrolytic IgG antibodies
[250]
B √ Distinguished between survivors and non-survivors at 28 days,
correlation with SAPS II score
Inter-alpha inhibitor
proteins (IalphaIp) [251]
C √ Predicted development of MOF
Intracellular nitric oxide in
leukocyte [252]
B √ Negatively correlated with SOFA score
IP-10 [30] C Increased in sepsis compared with healthy controls
Lactate [253,254] C √ Distinguished between survivors and non-survivors at 28 days,
predicted response to therapy
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Page 8 of 18No biomarker has, therefore, established itself suffi-
ciently to be of great help to clinicians in everyday clini-
cal practice. As each biomarker has limited sensitivity
and specificity, it may be interesting to combine several
biomarkers [40,41]; however, this hypothesis requires
further study. A clinical study showed that the combina-
tion of aPTT waveform with PCT increased the
specificity of the aPTT waveform in the diagnosis of
sepsis [35]. Studies using pa n e l so fs e p s i sb i o m a r k e r s
have also provided encouraging results [42-44]. The
cost-effectiveness of all these methods must also be
evaluated.
In this study, we tried to categorize the sepsis biomar-
kers according to their pathophysiological role in sepsis.
Table 9: Other biomarkers identified in the literature search (with some selected references) (Continued)
Lactoferrin [255,256] √ C(s) Predicted response to therapy
Leptin [240,257] √ B √ No prognostic value, higher in septic than in non-septic ICU
patients
Serum lysozyme (enzyme
activity) [258]
B(s) Increased in sepsis compared with healthy controls
Matrix-metalloproteinase
(MMP)-9 [259]
B Increased in severe sepsis compared with healthy controls
Microparticles (cell derived)
[252]
B √ Distinguished between survivors and non-survivors at 28 days,
correlation with SOFA score
Neurotensin [260] √
Nitrate excretion (urinary
and expired) [261]
√
Nociceptin/orphanin FQ (N/
OFQ) [262]
A √ Distinguished between survivors and non-survivors at 28 days
NF-B (activity and
expression) [263]
B √** Distinguished between survivors and non-survivors at 28 days
in patients with severe sepsis, correlation with APACHE II score
Nucleosomes [264] C Distinguished between survivors and non-survivors at 28 days
Peptidoglycan [265] B(s) √ Increased in sepsis compared with healthy controls
PlGF [266] √
Plasma amino acids
[267-269]
A √ Distinguished between survivors and non-survivors at 28 days,
predicted development of MOF
Plasma fibronectin [270] B √ Increased in sepsis compared with healthy controls
Plasmin alpha2-antiplasmin
complex [271]
C Predicted development of MOF
Renin [272] B √ Correlation with lactate levels in patients with septic shock
Resistin [273] C √ Correlation with APACHE II score in patients with severe sepsis
Selenium [274] C √ Correlation with APACHE II in patients with severe sepsis
Selenoprotein P [275] B Decraesed in sepsis compared with healthy controls
Serum bicarbonate [276] A(m) √ Predicted development of septic shock in neutropenic patients
Sphingomyelinase (enzyme
activity) [277]
A Distinguished between survivors and non-survivors at 28 days
in patients with severe sepsis
Sulfite [278] √ B(m) √ Predicted response to therapy
Transforming growth factor
(TGF)-b1 [279,280]
√ A(m) Distinguished between survivors and non-survivors at 28 days
TIMP-1 and 2 [259] B √* Distinguished between survivors and non-survivors at 28 days
TIMP-3 [281] √
Uric acid [282] C(s) √ Decreased in postoperative patients with sepsis compared
with those with no sepsis
Urinary 8-OhdG [283] C √ Distinguished between survivors and non-survivors at 28 days
Urinary bilirubin oxidative
metabolites (BOMs) [284]
A √ Correlation with APACHE II score
Annexin V binding [285] √ B(s) Increased in sepsis compared with healthy controls
Xanthine oxidase (activity)
[286]
C √ Distinguished between survivors and non-survivors at 28 days
*sensitivity and specificity of less than 90%; **sensitivity of more than 90% but specificity of less than 90%; A, Clinical study with less than 20 patients; B, Clinical
study with 20 to 50 patients; C, Clinical study with more than 50 patients; (s), surgical patients only; (m), medical patients only.
APACHE: acute physiology and chronic health evalution; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-macrophage colony stimulating factor;
MOF: multiple organ failure; NF-B: nuclear factor kappa B; PlGF: placental growth factor; SAPS: simplified acute physiology score; SOFA: sequential organ failure
assessment; TIMP: tissue inhibitor of metalloproteinase.
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Page 9 of 18Table 10 Biomarkers that have been assessed for use in the diagnosis of sepsis
Sepsis biomarker Clinical
study
Type of
measurement
Outcome
1 aPTT** [35] Cc High negative predictive value
2 CD11b*** [33] Bs Higher values in neonates with sepsis than in those with possible infection
3 CD25 [87] As Distinguished between sepsis and SIRS
4 CD64*** [32,287] Cs Low sensitivity and specificity to distinguish between viral and bacterial
infections
5 Complement (C3, C4, C5a) [219] Bs Distinguished between sepsis and SIRS
6 EA complex [230] Cs Diagnosis of sepsis, increased earlier than CRP
7 ELAM-1 (cellular and soluble)
[129]
C(s) c Increased in trauma patients with sepsis compared with no sepsis
8 Endocan [127] Bs Distinguished between sepsis and SIRS
9 E-Selectin (cellular and soluble)
[136]
Bs Distinguished between sepsis and SIRS
10 Fibrin degradation products [36] Bs High negative predictive value
11 Gas6 [241] Bs Higher values in patients with severe sepsis compared with patients with organ
failure but no sepsis
12 G-CSF [237] Cs Distinguished between sepsis and SIRS
13 Gelsolin [238] B(s) c Higher in septic patients compared with patients without sepsis
14 IL-1 receptor antagonist [55] Cs Early diagnosis of sepsis before symptoms in newborns
15 IL-8* [61] Cs Higher in septic neutropenic patients compared with febril neutropenic
patients without sepsis
16 IL-10 [65] As Higher in septic shock compared with cardiogenic shock
17 IL-12*** [29] Cs Diagnosis of sepsis in pediatric patients
18 IL-18 [70] B(s) s Distinguished between Gram-positive and Gram-negative sepsis. Higher in
trauma patients with sepsis than in those without
19 IP-10*** [30] Cs Early diagnosis of sepsis in newborns
20 Laminin [38] As Distinguished between Candida sepsis and bacterial sepsis
21 LBP [204] Cs Distinguished between Gram-positive sepsis and Gram-negative
22 MCP-1 [61] Cs Distinguished between sepsis and SIRS in neutropenic pediatric patients
23 NO, nitrate, nitrite [161] Bs Higher in septic shock compared with cardiogenic shock
24 Osteopontin [75] Bs Distinguished between sepsis and SIRS
25 PAI-1 [118] Bs Higher in patients with sepsis and DIC compared with no-septic patients with
DIC
26 Pentraxin 3 [207] Cs Distinguished between septic shock and SIRS
27 Peptidoglycan [262] B(s) c Higher in postoperative patients with infection compared with no-infected
postoperative patients
28 pFN [270] Bs Distinguished between sepsis and SIRS
29 PLA2-II (soluble)*** [31] Bs Distinguished between bacteremic and non-bacteremic infections
30 Serum lysozyme (enzyme
activity) [258]
Bs Distinguished between sepsis and organ rejection in transplanted patients
31 ST2 (soluble) [108] As Higher in septic patients compared with those with no sepsis
32 Surfactant protein (A, B, C, D)
[192]
Bs Early diagnosis of ARDS in septic patients
33 TREM-1 (soluble) [288,289] Cs Distinguished between sepsis and SIRS, diagnosed pneumonia
34 Troponin [193] Bs Diagnosis of myocardial dysfunction in septic patients
*sensitivity and specificity of less than 90%; **sensitivity of more than 90% but specificity of less than 90%; ***sensitivity and specificity more than 90%; A,
Clinical study with less than 20 patients; B, Clinical study with 20 to 50 patients; C, Clinical study with more than 50 patients; (s), surgical patients only; (m),
medical patients only; s, single value; c, values over time.
aPTT: activated partial thromboplastin time; ARDS: acute respiratory distress syndrome; CRP: C-reactive protein; DIC: disseminated intravascular coagulopathy; EA:
elastase alpha 1-proteinase inhibitor; ELAM: endothelial leukocyte adhesion molecule; G-CSF: granulocyte colony-stimulating factor; IP: interferon-induced protein;
LBP: lipopolysaccharide-binding protein; MCP: monocyte chemotactic protein; NO: nitric oxide; PAI: plasminogen activator inhibitor; pFN: plasma fibronectin;
PLA2: phospholipase A2; SIRS: systemic inflammatory response syndrome; TREM: triggering receptor expressed on myeloid cells.
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r u l eo u ts e p s i s ,b u ti ts h o u l da l s ob ea b l et ob eu s e dt o
guide therapy. It has been shown that using PCT levels
to guide therapy reduces antibiotic use and may be asso-
ciated with improved outcomes [45,46]. The use of
novel therapies that modify the pathophysiological pro-
cess of sepsis may also be guided by biomarkers [47,48].
A study is underway to evaluate the value of protein C
levels to guide the administration of activated protein C
(clinicaltrials.gov identifier NCT00386425). In the future,
sepsis biomarkers may help us administer these thera-
pies to the right patient at the right time.
Conclusions
Our literature review indicates that there are many bio-
markers that can be used in sepsis, but none has suffi-
cient specificity or sensitivity to be routinely employed
in clinical practice. PCT and CRP have been most
widely used, but even these have limited abilities to dis-
tinguish sepsis from other inflammatory conditions or
to predict outcome. In view of the complexity of the
sepsis response, it is unlikely that a single ideal biomar-
ker will ever be found. A combination of several sepsis
b i o m a r k e r sm a yb em o r ee f f e c t i v e ,b u tt h i sr e q u i r e s
further evaluation.
Key messages
￿ More than 170 different biomarkers have been
assessed for potential use in sepsis, more for prognosis
than for diagnosis.
￿ None has sufficient specificity or sensitivity to be
routinely employed in clinical practice.
￿ Combinations of several biomarkers may be more
effective than single biomarkers, but this requires
further evaluation.
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